司库奇尤单抗治疗成人扁平苔藓:随机安慰剂对照PRELUDE概念验证研究的疗效与安全性
PRELUDE研究纳入111例外用糖皮质激素控制不佳的皮肤、黏膜或毛发扁平苔藓成人患者,随机接受司库奇尤单抗300mg每4周或安慰剂16周后换用司库奇尤单抗300mg每2周。16周主要终点未达到,黏膜和毛发亚组IGA≤2应答率数值上高于安慰剂,皮肤亚组无应答。安全性与其他适应症已知特征一致。
要点
- 司库奇尤单抗300mg每4周在黏膜和毛发扁平苔藓中显示数值上更高的IGA≤2应答率
- 皮肤扁平苔藓亚组未观察到应答,三个亚组概念验证标准均未达到
- 安全性与其他适应症已知特征一致,未发现新信号
核心结论
- 司库奇尤单抗在黏膜和毛发扁平苔藓中显示数值上更高的IGA≤2应答率,但皮肤扁平苔藓无应答,主要终点未达到。
- 研究提示IL-17A在不同扁平苔藓亚型中可能作用不同。
研究设计与样本
- 随机双盲安慰剂对照II期概念验证篮子试验,纳入111例活检证实的皮肤、黏膜或毛发扁平苔藓成人患者,每个亚组37例。
- 患者随机接受司库奇尤单抗300mg每4周32周,或安慰剂16周后序贯司库奇尤单抗300mg每2周16周。
- 主要终点为第16周达到新设计的研究者总体评估(IGA)≤2。
主要发现
- 黏膜扁平苔藓亚组第16周IGA≤2应答率司库奇尤单抗组37.5%(95%CrI 20.3-57.2),安慰剂组23.1%(95%CrI 6.5-49.2)。
- 毛发扁平苔藓亚组第16周IGA≤2应答率司库奇尤单抗组37.5%(95%CrI 20.2-57.3),安慰剂组30.8%(95%CrI 10.8-57.6)。
- 毛发扁平苔藓亚组司库奇尤单抗组IGA≤2应答第16周37.5%、第32周45.8%;安慰剂交叉至每2周组第32周达63.6%。
- 安全性特征与司库奇尤单抗已知特征一致,未发现新或意外信号。
关键数值与推荐
- 主要终点为第16周IGA≤2;三个亚组均未达到概念验证标准,主要目标未达成。
- 新IGA评分与患者和医生报告结局指标均显示显著相关性。
临床怎么用
- 司库奇尤单抗在黏膜和毛发扁平苔藓中显示数值上改善趋势,但证据尚不足以支持常规使用。
- 皮肤扁平苔藓患者未观察到应答,不建议基于此研究使用司库奇尤单抗。
- 治疗选择仍需个体化,需结合亚型和患者具体情况。
局限性
- 概念验证研究样本量较小,每个亚组仅37例。
- 主要终点未达到,结果为数值性描述,未进行正式统计学检验。
- 研究未报告皮肤扁平苔藓亚组的具体应答数值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with lichen planus (LP) refractory to available therapies often experience a high disease burden, representing a population with a clear unmet need for new treatments. OBJECTIVES: To evaluate the efficacy and safety of secukinumab 300 mg over 32 weeks in adult patients with biopsy-proven cutaneous LP (CLP), mucosal LP (MLP) or lichen planopilaris (LPP) that is inadequately controlled by topical corticosteroids. METHODS: PRELUDE was a randomized double-blind placebo-controlled phase II proof-of-concept study that enrolled patients with CLP, MLP or LPP. Eligible patients were randomized to either secukinumab 300 mg every 4 weeks for 32 weeks (SECQ4W) or placebo for 16 weeks followed by secukinumab 300 mg every 2 weeks (SECQ2W) for 16 weeks. The primary endpoint was achievement of the newly designed Investigator's Global Assessment (IGA) score ≤ 2 at week 16. RESULTS: Overall, 111 patients were randomized (n = 37 each) to CLP, MLP and LPP cohorts. As the proof-of-concept criteria were not met for any of the three cohorts, the primary objective was not met. A numerically higher proportion of patients achieved IGA ≤ 2 response at week 16 with SECQ4W vs. placebo in the MLP {37.5% [95% credibility interval (Crl) 20.3-57.2] vs. 23.1% (95% Crl 6.5-49.2)} and LPP cohorts [37.5% (95% Crl 20.2-57.3) vs. 30.8% (95% Crl 10.8-57.6)]. In the LPP cohort, a sustained response for IGA ≤ 2 from week 16 to week 32 was achieved with SECQ4W (week 16, 37.5%; week 32, 45.8%), and a substantial improvement was observed in IGA ≤ 2 response in patients from this cohort who switched from placebo (week 16, 30.8%) to SECQ2W after week 16 (week 32, 63.6%). The safety profile was consistent with the known profile of secukinumab and showed no new or unexpected signals. CONCLUSIONS: PRELUDE is the first randomized controlled basket trial evaluating interleukin (IL)-17A inhibition with secukinumab across three subtypes of LP. Secukinumab was well tolerated and safe, showing different response rates across the three subtypes, with numerical IGA improvements in MLP and LPP, and no response in CLP. The study raises the question of a differential role of IL-17A across LP subtypes. The novel IGA score showed significant correlation with both patient- and physician-reported outcome measurements. Lichen planus (LP) is a skin disease that causes itchy, reddish-purple bumps on the skin. LP can affect different parts of the body, including the skin, mouth, genitals and nails. People with LP often experience intense itch, pain and discomfort, which can affect their daily lives. Secukinumab is a drug specifically designed to target and block a protein called ‘interleukin-17A’, which is found in high amounts in the lesions of LP. We carried out a clinical study to look at the effect of secukinumab separately in three different types of LP: cutaneous LP (CLP), mucosal LP (MLP) and lichen planopilaris (LPP). The study was conducted in the USA, France and Germany. A total of 111 adults who had not responded to topical treatment (treatment applied directly on the skin) took part in the study. Patients were divided into two groups. In one group, patients were treated with secukinumab 300 mg every 4 weeks for 16 weeks and continued with the treatment for another 16 weeks. In the other group, patients received placebo for 16 weeks and then received secukinumab 300 mg every 2 weeks for the next 16 weeks. All the patients were followed up for 8 weeks after stopping treatment. We measured whether secukinumab could reduce symptoms associated with LP using both doctor- and patient-assessed severity and quality-of-life measures. We also measured the side-effects related to the drug. We found that secukinumab was safe for people with LP, but it did not substantially reduce symptoms in people with CLP and only showed a tendency for improvement in people with MLP and LPP.
引用
- Passeron T, Reinhardt M, Ehst B, et al. Secukinumab in adult patients with lichen planus: efficacy and safety results from the randomized placebo-controlled proof-of-concept PRELUDE study. Br J Dermatol. 2024. PMID: 38735684. doi:10.1093/bjd/ljae181
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。